Status:
COMPLETED
The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19
Lead Sponsor:
Chinese Medical Association
Conditions:
Berberine
COVID-19
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Coronavirus disease 2019 (COVID-19) rapidly spread across China and throughout the world, causing hundreds of thousands died. Studies had shown that "cytokine storms" and subsequent multiple organ dys...
Detailed Description
Patients aged 18-80 years who confirmed with COVID-19 and classified as severe were enrolled in the study, and then separated randomly into two groups: a berberine group (B group) and a control group ...
Eligibility Criteria
Inclusion
- Patients confirmed with COVID-19 and classified as severe
Exclusion
- inflammatory bowel disease;
- have other sources of infection;
- death is anticipate within 72 hours;
- participated in other clinical trials;
- pregnant or lactating women;
Key Trial Info
Start Date :
February 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 23 2020
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT04479202
Start Date
February 8 2020
End Date
April 23 2020
Last Update
July 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China, 210008